Journal of the cardiometabolic syndrome最新文献_第8页

Statin Pleiotropy Against Renal Injury 他汀类药物多效性抗肾损伤

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00052.x

Michael S. Kostapanos MD, Evangelos N. Liberopoulos MD, Moses S. Elisaf MD

{"title":"Statin Pleiotropy Against Renal Injury","authors":"Michael S. Kostapanos MD, Evangelos N. Liberopoulos MD, Moses S. Elisaf MD","doi":"10.1111/j.1559-4572.2008.00052.x","DOIUrl":"10.1111/j.1559-4572.2008.00052.x","url":null,"abstract":"Statins may exhibit significant renoprotective effects beyond their lipid-lowering capacity. Herein, the authors review data from human and animal models of renal disease as well as from studies in cultured renal cells with regard to extralipid renoprotective properties of statins. Statins may exert lipid-independent benefits against renal injury in experimental states of chronic or acute renal function impairment. These include diabetic and hypertensive glomerulosclerosis, autoimmune glomerulonephritis, ischemia/reperfusion-induced renal damage, and unilateral ureteral obstructive nephropathy. Also, statins, by reducing the synthesis of mevalonate products, inhibit the activation of Rho and Ras guanosine triphosphatases that may influence various signaling pathways involving renal inflammatory, fibrogenic, proliferative, and cell-death responses. Therefore, statins exert anti-inflammatory actions in renal tissue, prevent renal scarring, and diminish mesangial or other kidney cell–type proliferation while promoting mesangial cell apoptosis. Renal antioxidant effects with consequent endothelial function regulation of renal vasculature following statin treatment may also account for pleiotropic protection against renal injury.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 1","pages":"E4-E9"},"PeriodicalIF":0.0,"publicationDate":"2009-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00052.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28008104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Waist Circumference, Body Mass Index, and Their Association With Cardiometabolic and Global Risk 腰围、体重指数及其与心脏代谢和全球风险的关系

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00029.x

Allison H. Christian EdD, Heidi Mochari MPH, RD, Lori J. Mosca MD, PhD

{"title":"Waist Circumference, Body Mass Index, and Their Association With Cardiometabolic and Global Risk","authors":"Allison H. Christian EdD, Heidi Mochari MPH, RD, Lori J. Mosca MD, PhD","doi":"10.1111/j.1559-4572.2008.00029.x","DOIUrl":"10.1111/j.1559-4572.2008.00029.x","url":null,"abstract":"Total body fat and adipose tissue distribution are associated with cardiometabolic risk, yet there are conflicting data as to whether waist circumference (WC) or body mass index (BMI) is a better predictor of cardiovascular risk. To determine whether WC or BMI was more strongly associated with cardiometabolic risk, family members of patients with cardiac disease were studied (N=501; mean age, 48 years; 66% female; 36% nonwhite). Height, weight, WC, BMI, blood pressure, high-density lipoprotein cholesterol, triglycerides, glucose, high-sensitivity C-reactive protein, and lipoprotein-associated phospholipase A2 were systematically measured. Global risk was calculated using the Framingham function. Increased WC and BMI were equally strong predictors of cardiometabolic and global risk. The prevalence of cardiometabolic risk factors and their correlation with WC and BMI varied by race/ethnicity. Our data support inclusion of WC and BMI in screening guidelines for diverse populations to identify individuals at increased cardiometabolic risk.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 1","pages":"12-19"},"PeriodicalIF":0.0,"publicationDate":"2009-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00029.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28008107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 56

Drugs Are Not Enough: The Metabolic Syndrome—A Call for Intensive Therapeutic Lifestyle Change 药物是不够的:代谢综合征——呼吁强化治疗改变生活方式

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00031.x

Todd M. Brown MD, Bonnie K. Sanderson PhD, RN, Vera Bittner MD, MSPH

{"title":"Drugs Are Not Enough: The Metabolic Syndrome—A Call for Intensive Therapeutic Lifestyle Change","authors":"Todd M. Brown MD, Bonnie K. Sanderson PhD, RN, Vera Bittner MD, MSPH","doi":"10.1111/j.1559-4572.2008.00031.x","DOIUrl":"10.1111/j.1559-4572.2008.00031.x","url":null,"abstract":"Whether intensive pharmacologic cardiovascular risk factor management reduces metabolic syndrome (MetS) prevalence is unknown. The authors compared the number of secondary prevention medications and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)–defined MetS prevalence in coronary artery disease patients entering cardiac rehabilitation from 1996 to 2001 (period 1, n=516) with those entering from 2002 to 2006 (period 2, n=609). Age, sex, and ethnicity were similar in both periods. From period 1 to period 2, participants took more secondary prevention medications (2.8±1.3 vs 3.5±1.0, P<.001). Prevalence of low high-density lipoprotein cholesterol (66% vs 66%), diabetes (37% vs 38%), and hypertension (81% vs 81%) were unchanged. The prevalence of hypertriglyceridemia decreased (48% vs 36%, P<.001), but the proportion meeting criteria for elevated waist circumference increased (51% vs 58%, P<.05), resulting in no change in overall MetS prevalence (60% vs 59%, P=NS). More emphasis on therapeutic lifestyle change in addition to intensive pharmacologic therapy is needed to reduce MetS prevalence in patients with coronary artery disease.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 1","pages":"20-25"},"PeriodicalIF":0.0,"publicationDate":"2009-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00031.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28008108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

The Role of Adiponectin in Obesity, Diabetes, and Cardiovascular Disease 脂联素在肥胖、糖尿病和心血管疾病中的作用

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00030.x

Jordan Kawano BA, Rohit Arora MD, FACC

引用次数: 188

The Role of the Renin-Angiotensin System in the Pathophysiology, Prevention, and Treatment of Renal Impairment in Patients With the Cardiometabolic Syndrome or Its Components 肾素-血管紧张素系统在心脏代谢综合征或其组成部分患者肾脏损害的病理生理、预防和治疗中的作用

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00035.x

Martin A. Alpert MD, Gurushankar Govindarajan MD, Marc L.E. Del Rosario MD, Efrain Reisin MD

{"title":"The Role of the Renin-Angiotensin System in the Pathophysiology, Prevention, and Treatment of Renal Impairment in Patients With the Cardiometabolic Syndrome or Its Components","authors":"Martin A. Alpert MD, Gurushankar Govindarajan MD, Marc L.E. Del Rosario MD, Efrain Reisin MD","doi":"10.1111/j.1559-4572.2008.00035.x","DOIUrl":"10.1111/j.1559-4572.2008.00035.x","url":null,"abstract":"Chronic kidney disease and cardiovascular disease share many risk factors, including hypertension, obesity, and insulin resistance. All of these are components of the cardiometabolic syndrome and are associated with increased risk of morbidity and mortality. One mechanism that links renal injury with the cardiometabolic syndrome is activation of the renin-angiotensin system. Chronic angiotensin II activation promotes development of renal disease through hemodynamic effects and up-regulation of inflammatory cytokines and growth factors. Inhibition of the renin-angiotensin system delays progression of renal disease and improves measures of renal function independent of blood pressure lowering in patients with the cardiometabolic syndrome or its components. Higher doses of renin-angiotensin system inhibitors may provide greater renoprotection in both normotensive and hypertensive patients with the cardiometabolic syndrome. Inhibition of the renin-angiotensin system in patients with risk factors or vascular disease with or without recognized glycemic abnormalities may be a useful strategy for preventing the progression of chronic kidney disease in patients with vascular disease and in those with the cardiometabolic syndrome or its components.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 1","pages":"57-62"},"PeriodicalIF":0.0,"publicationDate":"2009-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00035.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28008534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Antihypertensive Pharmacotherapy: Adverse Effects of Medications Promote Nonadherence 抗高血压药物治疗:药物的不良反应促进不依从

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00053.x

Icilma V. Fergus MD

引用次数: 8

Coronary Artery Calcification and Inflammation According to Various Metabolic Syndrome Definitions 根据各种代谢综合征定义的冠状动脉钙化和炎症

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00033.x

Venkata Narla BA, Raul D. Santos MD, PhD, Catherine Y. Campbell MD, Jose A.M. Carvalho MD, Khurram Nasir MD, MPH, Matthew J. Budoff MD, Roger S. Blumenthal MD, Erin D. Michos MD, MHS

{"title":"Coronary Artery Calcification and Inflammation According to Various Metabolic Syndrome Definitions","authors":"Venkata Narla BA, Raul D. Santos MD, PhD, Catherine Y. Campbell MD, Jose A.M. Carvalho MD, Khurram Nasir MD, MPH, Matthew J. Budoff MD, Roger S. Blumenthal MD, Erin D. Michos MD, MHS","doi":"10.1111/j.1559-4572.2008.00033.x","DOIUrl":"10.1111/j.1559-4572.2008.00033.x","url":null,"abstract":"A number of metabolic syndrome (MS) definitions exist, and one’s cardiovascular disease risk may depend on the definition used. The authors compared the association of subclinical atherosclerosis (coronary artery calcification [CAC] score >0] and inflammation (white blood cell [WBC] count greater than or equal to the highest quartile) with 3 definitions of MS (those of the National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III], the American Heart Association/National Heart, Lung and Blood Institute [AHA/NHLBI], and the International Diabetes Federation [IDF]) in 458 asymptomatic men (mean age, 46±7 years). MS was present in 28%, 29%, and 34% according to NCEP ATP III, AHA/NHLBI, and IDF criteria, respectively. CAC was observed in 40% and high WBC count in 24%. After adjustment for age, smoking, and low-density lipoprotein cholesterol, the odds ratios for CAC scores >0 with MS by NCEP ATP III, AHA/NHLBI, and IDF definitions were 1.67 (95% confidence interval [CI], 1.02–2.72), 1.67 (95% CI, 1.03–2.70), and 1.63 (95% CI, 1.03–2.57), respectively. The multivariate odds ratios for high WBC count with MS by NCEP ATP III, AHA/NHLBI, and IDF definitions were 1.69 (95% CI, 1.04–2.73), 1.84 (95% CI, 1.14–2.95), and 1.66 (95% CI, 1.05–2.62), respectively. MS is associated with increased subclinical atherosclerosis and inflammation irrespective of various definitions.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 1","pages":"33-39"},"PeriodicalIF":0.0,"publicationDate":"2009-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00033.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28008110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Prevalence and Significance of Cardiometabolic Risk Factors in Children With Type 1 Diabetes 1型糖尿病儿童心脏代谢危险因素的患病率及意义

Journal of the cardiometabolic syndrome Pub Date : 2009-02-20 DOI: 10.1111/j.1559-4572.2008.00034.x

Sowmya Krishnan MD, Kevin R. Short PhD

{"title":"Prevalence and Significance of Cardiometabolic Risk Factors in Children With Type 1 Diabetes","authors":"Sowmya Krishnan MD, Kevin R. Short PhD","doi":"10.1111/j.1559-4572.2008.00034.x","DOIUrl":"10.1111/j.1559-4572.2008.00034.x","url":null,"abstract":"Type 1 diabetes (T1D) is a common disease of childhood with a current prevalence of almost 2 cases per 1000 adolescents, according to the third National Health and Nutrition Examination Survey. Modern insulin treatment has resulted in improved quality of life for children with this chronic disorder. However, T1D continues to carry a long-term burden of increased microvascular and macrovascular complications and mortality risk. Compared to the nondiabetic population, patients with T1D are more likely to have ≥1 cardiovascular risk factor and often at an earlier age. Since the prevalence of cardiovascular risk factors increases with age in young persons with T1D, there is a clear need for early screening and counseling to prevent their occurrence and manage long-term health ramifications. The purpose of this review is to describe how traditional risk factors for cardiovascular disease such as an abnormal lipid profile, hypertension, obesity, and insulin resistance contribute to the accelerated atherosclerosis seen in young persons with T1D. A summary is given of the guidelines and recommendations published for clinical care for these patients.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"4 1","pages":"50-56"},"PeriodicalIF":0.0,"publicationDate":"2009-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00034.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28008535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 45

Demographic Analyses of the Effects of Carvedilol vs Metoprolol on Glycemic Control and Insulin Sensitivity in Patients With Type 2 Diabetes and Hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) Study 卡维地洛与美托洛尔对2型糖尿病合并高血压患者血糖控制和胰岛素敏感性影响的人口学分析糖尿病的血糖作用:卡维地洛-美托洛尔在高血压患者中的比较(GEMINI)研究

Journal of the cardiometabolic syndrome Pub Date : 2008-11-24 DOI: 10.1111/j.1559-4572.2008.00017.x

Robert A. Phillips MD, PhD, Vivian Fonseca MD, Richard E. Katholi MD, Janet B. McGill MD, Franz H. Messerli MD, David S.H. Bell MD, Philip Raskin MD, Jackson T. Wright Jr MD, PhD, Malini Iyengar PhD, Karen M. Anderson PhD, Mary Ann Lukas MD, George L. Bakris MD, for the GEMINI Investigators

{"title":"Demographic Analyses of the Effects of Carvedilol vs Metoprolol on Glycemic Control and Insulin Sensitivity in Patients With Type 2 Diabetes and Hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) Study","authors":"Robert A. Phillips MD, PhD, Vivian Fonseca MD, Richard E. Katholi MD, Janet B. McGill MD, Franz H. Messerli MD, David S.H. Bell MD, Philip Raskin MD, Jackson T. Wright Jr MD, PhD, Malini Iyengar PhD, Karen M. Anderson PhD, Mary Ann Lukas MD, George L. Bakris MD, for the GEMINI Investigators","doi":"10.1111/j.1559-4572.2008.00017.x","DOIUrl":"10.1111/j.1559-4572.2008.00017.x","url":null,"abstract":"In the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial, carvedilol added to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers had neutral or beneficial effects on glycemic measures compared with metoprolol tartrate. For the 1235 diabetic hypertensive GEMINI patients, the authors assessed treatment differences by race (white/black/other), age (continuous variable), and sex on hemoglobin A1c, insulin resistance (homeostasis model assessment–insulin resistance [HOMA-IR]), and blood pressure. Both treatments significantly reduced blood pressure in all subgroups, but the metabolic effects of carvedilol were more beneficial in subgroups of race and sex. Carvedilol did not affect hemoglobin A1c but improved HOMA-IR results in all subgroups, significantly in males and “other race” subgroups. Metoprolol significantly increased hemoglobin A1c in all subgroups except “other race,” with no effect on HOMA-IR findings. Differences vs metoprolol significantly favored carvedilol for hemoglobin A1c in white and female subgroups and favored carvedilol for HOMA-IR in black, “other race,” and male subgroups. Carvedilol effects were favorable to adjustment of age as a covariate. In hypertensive patients with diabetes, carvedilol may be a more appropriate choice when β-blockade is indicated.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"3 4","pages":"211-217"},"PeriodicalIF":0.0,"publicationDate":"2008-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00017.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27865647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

The Metabolic Syndrome Among Patients Undergoing Cardiac Catheterization in Jordan 约旦心导管置入术患者的代谢综合征

Journal of the cardiometabolic syndrome Pub Date : 2008-11-24 DOI: 10.1111/j.1559-4572.2008.00020.x

Yousef Khader BDS, MSc, MSPH, MHPE, ScD, Moawiah Khatatbeh RN, MSc, Khalid EL-Salem MD, Zouhair Amarin MD, MSc, Anwar Bateiha MD, DrPH

{"title":"The Metabolic Syndrome Among Patients Undergoing Cardiac Catheterization in Jordan","authors":"Yousef Khader BDS, MSc, MSPH, MHPE, ScD, Moawiah Khatatbeh RN, MSc, Khalid EL-Salem MD, Zouhair Amarin MD, MSc, Anwar Bateiha MD, DrPH","doi":"10.1111/j.1559-4572.2008.00020.x","DOIUrl":"10.1111/j.1559-4572.2008.00020.x","url":null,"abstract":"This study was conducted to determine the prevalence of the metabolic syndrome (MeS) and its associated factors among patients undergoing cardiac catheterization in north Jordan. A cross-sectional study was conducted among patients who underwent cardiac catheterization at King Abdullah University Hospital in north Jordan. Data from 360 patients were collected through personal interview, medical records, and anthropometric measurements. MeS was defined using National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and International Diabetes Federation (IDF) criteria. The prevalence of MeS among patients undergoing cardiac catheterization in north Jordan was 64.7% according to NCEP ATP III criteria and 76.7% according to IDF criteria. About 96.7% of the participants had at least 1 metabolic abnormality. Sex, body mass index, and family history of cardiovascular disease were the only variables significantly associated with MeS. The prevalence of MeS among patients undergoing cardiac catheterization in north Jordan is considerably high, especially among women.","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"3 4","pages":"224-228"},"PeriodicalIF":0.0,"publicationDate":"2008-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00020.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27865649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8